Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

New report offers a blueprint for prudent investments in technology, through which governments can create effective and fair health and education services.

© Shutterstock

Well-considered investments in digital technology can be transformational for health and education services across the developing world, but too often they fail to deliver impact at scale, according to research released today by the Oxford University-based Pathways for Prosperity Commission on Technology and Inclusive Development.

Melinda Gates, co-chair of the Pathways Commission, said: “Better health and education for young people – the twin engines of what economists call ‘human capital’ – could drive the next phase of economic progress in developing countries, but only if governments design policies to ensure technology reaches the most marginalized communities.”

The Commission’s new report, Positive disruption: health and education in a digital agehas found that silver bullet initiatives, focussing only on technological hardware, such as introducing laptops in classrooms, are often not effective beyond the initial pilot. This is usually due to policy makers adopting a piecemeal approach, which fails to consider the wider system in which the technology is being used.

However, the research finds that by looking at entire health and education systems, and deploying technology at strategic points, countries can provide health and education that works for all.

Read more (University of Oxford website)

Similar stories

Singula Bio, a new Oxford spin-out company - Cancer need not be fatal

General Innovation Research

Singula Bio, a bold new seed-stage biotechnology company spun out of Oxford University, has been launched with the intention of helping show that cancer need not be fatal. Led by three Oxford cancer specialists, the firm is aims to become a world leader in therapies to use against difficult-to-treat solid malignancies such as ovarian cancer - using the body’s own immune system to fight previously fatal cancers.

Major rise in public support for COVID vaccine – Oxford study

Coronavirus COVID-19 General Research

More than three quarters of people in the UK now say they are ’very likely’ to have the vaccine – up from 50% among the same group of survey respondents five months ago –according to a two-wave Oxford University survey published today.

Coronavirus vaccination linked to substantial reduction in hospitalisation, real-world data suggests

Coronavirus COVID-19 General Research

The first study to describe the effects in real-world communities of the Oxford coronavirus vaccine has been reported in a pre-print publication today, showing a clear reduction in the risk of hospitalisation from COVID-19 amongst those who have received the vaccine.

World’s largest clinical trial for COVID-19 treatments expands internationally

Clinical Trials Coronavirus COVID-19 General

The Randomised Evaluation of COVID-19 Therapy (RECOVERY) Trial, the world’s largest clinical trial for COVID-19 treatments, has now expanded internationally with Indonesia and Nepal among the first countries to join. The first patients have been recruited to RECOVERY International.

Reprogramming tumour cells using an antimalarial drug

General Research

Results from the ATOM clinical trial at the University of Oxford have shown that the anti-malarial drug Atovaquone can reduce very low oxygen tumour environments. This has the potential to make cancers behave less aggressively and to improve the impact of everyday cancer treatments.